Carla M. Lopes

Prof. Carla M. Lopes

Faculty of Health Science, Fernando Pessoa University
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Carla M. LopesCarla M. Lopes
Carla M. Lopes
CBCatarina Bettencourt
Catarina Bettencourt
Alessandra RossiAlessandra Rossi
Alessandra Rossi
Francesca ButtiniFrancesca Buttini
Francesca Buttini
PBPedro Barata
Pedro Barata

2 November 2022 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Open access
MTMaria Inês Teixeira
Maria Inês Teixeira
Carla M. LopesCarla M. Lopes
Carla M. Lopes
MAMaria Helena Amaral
Maria Helena Amaral
PCPaulo C. Costa
Paulo C. Costa

1 November 2013 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
AMA.I. Mendes
A.I. Mendes
Ana Catarina SousaAna Catarina Sousa
Ana Catarina Sousa
José CatitaJosé Catita
José Catita
FCFatima Cerqueira
Fatima Cerqueira
CGC. Gabriel
C. Gabriel
Carla M. LopesCarla M. Lopes
Carla M. Lopes

1 August 2009 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
JAJ. Araújo
J. Araújo
EVE. Vega
E. Vega
Carla M. LopesCarla M. Lopes
Carla M. Lopes
MEM.A. Egea
M.A. Egea
MGM.L. Garcia
M.L. Garcia
Eliana B. SoutoEliana B. Souto
Eliana B. Souto

1 April 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
MTMaria Inês Teixeira
Maria Inês Teixeira
Carla M. LopesCarla M. Lopes
Carla M. Lopes
MAMaria Helena Amaral
Maria Helena Amaral
PCPaulo Jorge Cardoso da Costa
Paulo Jorge Cardoso da Costa

6 August 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Carla M. LopesCarla M. Lopes
Carla M. Lopes
ADA. Dourado
A. Dourado
RORita Oliveira
Rita Oliveira
Breast cancer is the most frequent type of nonskin malignancy among women worldwide. In general, conventional cancer treatment options (i.e., surgery, radiotherapy, chemotherapy, biological therapy, and hormone therapy) are not completely effective. Recurrence and other pathologic situations are still an issue in breast cancer patients due to side effects, toxicity of drugs in normal cells, and aggressive behaviour of the tumours. From this point of view, breast cancer therapy and adjuvant methods represent a promising and challenging field for researchers. In the last few years, the use of some types of complementary medicines by women with a history of breast cancer has significantly increased such as phytotherapeutic products and nutritional supplements. Despite this, the use of such approaches in oncologic processes may be problematic and patient’s health risks can arise such as interference with the efficacy of standard cancer treatment. The present review gives an overview of the most usual phytotherapeutic products and nutritional supplements with application in breast cancer patients as adjuvant approach. Regardless of the contradictory results of scientific evidence, we demonstrated the need to perform additional investigation, mainly well-designed clinical trials in order to establish correlations and allow for further validated outcomes concerning the efficacy, safety, and clinical evidence-based recommendation of these products.